Phase 3 Clinical Trial Results Indicate Efficacy of Marstacimab in Hemophilia A & B With Inhibitors

Click here for the open-access results of the anti-TFPI MOAB rebalancing therapy marstacimab (HYMPAVZI®): Matino D, Acharya SS, Taylor CT, et al. Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial. Blood. 2026;147:920–31. doi: 10.1182/blood.2025031065. PMID: 41351884. Abstract Marstacimab, a monoclonal antibody that inhibits tissue factor […]

Comments (0)

Bleeding Disorders

Mar 10 2026

george

Review: Acquired Hemostasis Disorders

See this open-access review on acquired hemostasis disorders: Tufano A, Franchini M, Coppola A. Acquired hemostasis disorders. Semin Thromb Hemost. 2026;52:277–9. doi: 10.1055/a-2788-1844. PMID: 41802449.

Bleeding Disorders

Anticoagulant Monitoring in ECMO

Here’s a provocative open-access essay that reviews the efficacy of current anticoagulant monitoring in ECMO: Rajsic S, Treml B. Anticoagulation monitoring during ECMO support: monitor or flip a coin? Clin Cardiol. 2024;47(12):e70061. doi: 10.1002/clc.70061. PMID: 39692163; PMCID: PMC11653157. Abstract Should we rely on anticoagulation monitoring in ECMO patients or simply flip a coin? The increasing […]

Comments (0)

Anticoagulant Therapy

Mar 10 2026

george

BioMarin Withdraws Roctavian

This announcement appears in BioMarin’s 2025 full-year financial report: “Following the company’s October announcement to explore options to divest ROCTAVIAN, BioMarin undertook a comprehensive effort to identify a potential buyer. Despite these efforts, BioMarin was unable to identify a qualified buyer and has decided to withdraw ROCTAVIAN from the market voluntarily.” There are no FVIII […]

Bleeding Disorders

Diagnostic Equity Case: Prolonged PTT

This question was posted on the Diagnostic Equity website on March 5, 2026: “My PT is normal at 12 seconds, but my PTT (aPTT, APTT) is elevated at 72 seconds. I had excessive bleeding after a dental procedure. My hematologist said a mixing study was done and it was corrected, so what does a mixing […]

Blog

Xarelto Sales Decline

Bayer said Wednesday 3-4-26 that it expects the erosion of Xarelto sales to “slightly accelerate” this year as the oral anticoagulant faces further competition from generics. Revenue from the product is forecast to fall by between 35% and 40% in 2026, compared to a roughly 33% decline last year to €2.3 billion ($2.7 billion). The company […]

Comments (1)

Anticoagulant Therapy

Mar 4 2026

george

Research Report Examines Efficacy of Chemiluminescence HIT Assay

Here is an open-access article describing the efficacy of a chemiluminescence HIT assay: Bowyer A, Kohama K, Patel I, et al’A new, rapid, chemiluminescence enzyme assay for the detection of heparin-induced thrombocytopenia: a comparison between functional and immune heparin-induced thrombocytopenia assays, Res Prac in Thrombosis and Haemostasis,2026;10, 103373, ISSN 2475-0379, https://doi.org/10.1016/j.rpth.2026.103373. Abstract Background Heparin-induced thrombocytopenia […]

Thrombophilia

Review: AI in Thrombosis and Hemostasis

Click here for this open-access article that describes AI in thrombosis and hemostasis. (This is the first time we’ve posted about AI). Altememi MA, Favaloro EJ, Islam MZ, Santhakumar AB. Artificial intelligence and machine learning in thrombosis and hemostasis: a scoping review of clinical and laboratory applications, challenges, and future directions. Clin Chem Lab Med. […]

Comments (0)

Global Hemostasis Assays

Mar 2 2026

george

Bleeding and Thrombosis in Chronic Kidney Disease

Click this open-access article on the adverse outcomes of anticoagulation in chronic kidney disease: Jones A, Swan D, Lisman T, Barnes GD, Thachil J. Anticoagulation in chronic kidney disease: current status and future perspectives. J Thromb Haemost. 2024;22:323–36. doi: 10.1016/j.jtha.2023.09.020. PMID: 37778512. Abstract Chronic kidney disease (CKD) is being diagnosed increasingly worldwide. It is often […]

Comments (0)

Anticoagulant Therapy

Mar 2 2026

george

Emicizumab Dosage

Here is an open-access article on current emicizumab dosage: van der Zwet K, de Vos ADW, Cnossen MH, et al; OPTI-CLOT Study Group and SYMPHONY Consortium. Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study. J Thromb Haemost. 2026;24:890–99. doi: 10.1016/j.jtha.2025.10.029. PMID: 41207564. Abstract Background Emicizumab provides effective prophylaxis […]

Comments (0)

Bleeding Disorders

All Posts

Phase 3 Clinical Trial Results Indicate Efficacy of Marstacimab in Hemophilia A & B With Inhibitors

Review: Acquired Hemostasis Disorders

Anticoagulant Monitoring in ECMO

BioMarin Withdraws Roctavian

Diagnostic Equity Case: Prolonged PTT

Xarelto Sales Decline

Research Report Examines Efficacy of Chemiluminescence HIT Assay

Review: AI in Thrombosis and Hemostasis

Bleeding and Thrombosis in Chronic Kidney Disease

Emicizumab Dosage

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question